Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis

Yong Seok Yun, Hyun Chul Lee, Chong Seok Park, Kyung Hee Chang, Chae Hwa Cho, Young Duk Song, Sung Kil Lim, Kyung Rae Kim, Kap Bum Huh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Insulin deficiency and counterregulatory hormone excess are the basic process in the development of diabetic ketoacidosis (DKA). Somatostatin, which suppresses the secretion of glucagon and growth hormone, has been known to attenuate the rate of gluconeogesis and ketogenesis in insulin-dependent diabetes mellitus patients. However, the therapeutic efficacy of somatostatin has not been approved to be practical in the treatment of manifest DKA. To examine the additive effect of octreotide, the synthetic long-acting somatostatin analogue SMS 201-995, to conventional treatment of manifest DKA, we compared the correction time of acidosis, ketonuria, and hyperglycemia of patients treated with an intravenous infusion of low-dose insulin (4 units per hour) plus subcutaneous injection of octreotide (50 μg every 6 hours) by low-dose insulin alone. The correction time for hyperglycemia and acidosis did not show any difference between groups (p = 0.089, p = 0.82). However, the time for disappearance of ketonuria of the octreotide-treated group (38.0 ± 32.0 h) was reduced significantly compared to other group (68.3 ± 26.0 h) (p = 0.048). These results indicated that the addition of octreotide to conventional treatment of DKA might improve the correction of ketosis, but would not allow more rapid control of acidosis and hyperglycemia in manifest DKA. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)288-292
Number of pages5
JournalJournal of Diabetes and its Complications
Volume13
Issue number5-6
DOIs
Publication statusPublished - 1999 Sep 1

Fingerprint

Diabetic Ketoacidosis
Octreotide
Somatostatin
Ketosis
Acidosis
Hyperglycemia
Insulin
Subcutaneous Injections
Therapeutics
Glucagon
Type 1 Diabetes Mellitus
Intravenous Infusions
Growth Hormone
Hormones

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Yun, Y. S., Lee, H. C., Park, C. S., Chang, K. H., Cho, C. H., Song, Y. D., ... Huh, K. B. (1999). Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. Journal of Diabetes and its Complications, 13(5-6), 288-292. https://doi.org/10.1016/S1056-8727(99)00059-8
Yun, Yong Seok ; Lee, Hyun Chul ; Park, Chong Seok ; Chang, Kyung Hee ; Cho, Chae Hwa ; Song, Young Duk ; Lim, Sung Kil ; Kim, Kyung Rae ; Huh, Kap Bum. / Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. In: Journal of Diabetes and its Complications. 1999 ; Vol. 13, No. 5-6. pp. 288-292.
@article{f816cf449c64481f8a9143b9b5e92f5c,
title = "Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis",
abstract = "Insulin deficiency and counterregulatory hormone excess are the basic process in the development of diabetic ketoacidosis (DKA). Somatostatin, which suppresses the secretion of glucagon and growth hormone, has been known to attenuate the rate of gluconeogesis and ketogenesis in insulin-dependent diabetes mellitus patients. However, the therapeutic efficacy of somatostatin has not been approved to be practical in the treatment of manifest DKA. To examine the additive effect of octreotide, the synthetic long-acting somatostatin analogue SMS 201-995, to conventional treatment of manifest DKA, we compared the correction time of acidosis, ketonuria, and hyperglycemia of patients treated with an intravenous infusion of low-dose insulin (4 units per hour) plus subcutaneous injection of octreotide (50 μg every 6 hours) by low-dose insulin alone. The correction time for hyperglycemia and acidosis did not show any difference between groups (p = 0.089, p = 0.82). However, the time for disappearance of ketonuria of the octreotide-treated group (38.0 ± 32.0 h) was reduced significantly compared to other group (68.3 ± 26.0 h) (p = 0.048). These results indicated that the addition of octreotide to conventional treatment of DKA might improve the correction of ketosis, but would not allow more rapid control of acidosis and hyperglycemia in manifest DKA. Copyright (C) 2000 Elsevier Science Inc.",
author = "Yun, {Yong Seok} and Lee, {Hyun Chul} and Park, {Chong Seok} and Chang, {Kyung Hee} and Cho, {Chae Hwa} and Song, {Young Duk} and Lim, {Sung Kil} and Kim, {Kyung Rae} and Huh, {Kap Bum}",
year = "1999",
month = "9",
day = "1",
doi = "10.1016/S1056-8727(99)00059-8",
language = "English",
volume = "13",
pages = "288--292",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "5-6",

}

Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis. / Yun, Yong Seok; Lee, Hyun Chul; Park, Chong Seok; Chang, Kyung Hee; Cho, Chae Hwa; Song, Young Duk; Lim, Sung Kil; Kim, Kyung Rae; Huh, Kap Bum.

In: Journal of Diabetes and its Complications, Vol. 13, No. 5-6, 01.09.1999, p. 288-292.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of long-acting somatostatin analogue (Sandostatin) on manifest diabetic ketoacidosis

AU - Yun, Yong Seok

AU - Lee, Hyun Chul

AU - Park, Chong Seok

AU - Chang, Kyung Hee

AU - Cho, Chae Hwa

AU - Song, Young Duk

AU - Lim, Sung Kil

AU - Kim, Kyung Rae

AU - Huh, Kap Bum

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Insulin deficiency and counterregulatory hormone excess are the basic process in the development of diabetic ketoacidosis (DKA). Somatostatin, which suppresses the secretion of glucagon and growth hormone, has been known to attenuate the rate of gluconeogesis and ketogenesis in insulin-dependent diabetes mellitus patients. However, the therapeutic efficacy of somatostatin has not been approved to be practical in the treatment of manifest DKA. To examine the additive effect of octreotide, the synthetic long-acting somatostatin analogue SMS 201-995, to conventional treatment of manifest DKA, we compared the correction time of acidosis, ketonuria, and hyperglycemia of patients treated with an intravenous infusion of low-dose insulin (4 units per hour) plus subcutaneous injection of octreotide (50 μg every 6 hours) by low-dose insulin alone. The correction time for hyperglycemia and acidosis did not show any difference between groups (p = 0.089, p = 0.82). However, the time for disappearance of ketonuria of the octreotide-treated group (38.0 ± 32.0 h) was reduced significantly compared to other group (68.3 ± 26.0 h) (p = 0.048). These results indicated that the addition of octreotide to conventional treatment of DKA might improve the correction of ketosis, but would not allow more rapid control of acidosis and hyperglycemia in manifest DKA. Copyright (C) 2000 Elsevier Science Inc.

AB - Insulin deficiency and counterregulatory hormone excess are the basic process in the development of diabetic ketoacidosis (DKA). Somatostatin, which suppresses the secretion of glucagon and growth hormone, has been known to attenuate the rate of gluconeogesis and ketogenesis in insulin-dependent diabetes mellitus patients. However, the therapeutic efficacy of somatostatin has not been approved to be practical in the treatment of manifest DKA. To examine the additive effect of octreotide, the synthetic long-acting somatostatin analogue SMS 201-995, to conventional treatment of manifest DKA, we compared the correction time of acidosis, ketonuria, and hyperglycemia of patients treated with an intravenous infusion of low-dose insulin (4 units per hour) plus subcutaneous injection of octreotide (50 μg every 6 hours) by low-dose insulin alone. The correction time for hyperglycemia and acidosis did not show any difference between groups (p = 0.089, p = 0.82). However, the time for disappearance of ketonuria of the octreotide-treated group (38.0 ± 32.0 h) was reduced significantly compared to other group (68.3 ± 26.0 h) (p = 0.048). These results indicated that the addition of octreotide to conventional treatment of DKA might improve the correction of ketosis, but would not allow more rapid control of acidosis and hyperglycemia in manifest DKA. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033549926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033549926&partnerID=8YFLogxK

U2 - 10.1016/S1056-8727(99)00059-8

DO - 10.1016/S1056-8727(99)00059-8

M3 - Article

C2 - 10765004

AN - SCOPUS:0033549926

VL - 13

SP - 288

EP - 292

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5-6

ER -